急性髓系白血病细胞高表达雄激素受体但不依赖雄激素信号存活
研究基于AML17和AML19试验中4281例接受强化化疗的急性髓系白血病患者分析性别与生存关系,发现男性缓解率显著低于女性且为独立不良预后因素。AML细胞高表达雄激素受体且与不良总生存相关,但体外和体内实验显示雄激素不影响原代AML细胞存活、基因表达或化疗保护作用。作者结论认为靶向雄激素通路可能不是有前景的临床策略,性激素信号不能解释男性更差预后。
要点
- 男性AML患者缓解率显著低于女性,且为独立生存不良因素。
- AML细胞各细胞遗传学风险组均高表达雄激素受体,其表达与不良总生存相关。
- 雄激素对原代AML细胞存活、基因表达及化疗保护均无影响。
核心结论
- 靶向雄激素通路可能不是有前景的临床策略,AML细胞性激素信号不能解释男性更差预后。
研究设计与样本
- 基于AML17和AML19试验中4281例接受强化化疗的急性髓系白血病患者进行性别与生存分析。
主要发现
- 男性缓解率显著低于女性,且不良细胞遗传学特征发生率更高、相对有利的NPM1突变发生率更低。
- 多因素分析中男性是生存的独立危险因素。
- AML各细胞遗传学风险组均高表达雄激素受体,其表达由IL-6信号在体外诱导且与不良总生存相关。
- 雄激素对原代AML细胞体外存活和基因表达无影响,体外和体内均不保护AML细胞抵抗化疗。
- 体外AML细胞中雌激素受体信号通路结果类似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Male sex is associated with worse outcome in acute myeloid leukemia (AML) in many studies. We analyzed the survival of 4281 patients treated with intensive chemotherapy in the AML17 and AML19 trials based on sex. Men had a significantly lower remission rate than women. Men had a higher incidence of adverse cytogenetic features and a lower incidence of the relatively favorable NPM1 mutation. However, male sex was an independent risk factor for survival in multi-variate analysis. We hypothesized that androgen signaling in men could worsen outcomes by protecting AML cells from chemotherapy. We demonstrated high levels of androgen receptor (AR) expression in AML across cytogenetic risk groups. We showed the AR expression was induced by IL-6 signaling in vitro and correlates with poor overall survival. Androgens had no effect on survival of primary AML cells in vitro, nor did they impact gene expression. Androgens did not protect AML cells against chemotherapy either in vitro or in vivo. Similar results were observed with estrogen signaling through estrogen receptor in vitro in AML cells. In conclusion, targeting the androgen pathway may not be a promising clinical strategy and sex hormone signaling in AML cells does not explain the poorer outcomes of men.
引用
- Miraki-Moud F, Ariza-McNaughton L, KoKo T, et al. Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival. Leukemia. 2025. PMID: 40935826. doi:10.1038/s41375-025-02752-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。